ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE

Objective: To compare mean heart rate reduction in Ivabradine and placebo group in left ventricular failure patients. Study Design: Quasi experimental study. Place and Duration of Study: Study was conducted at CMH, Kharian, from Jul 2018 to Dec 2018. Methodology: 64 patients participated i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Safia Batool, Jamal Waris, Muhammad Usman Sajid, Shazia Nisar, Imran Khan, Hina Mushtaq
Formato: article
Lenguaje:EN
Publicado: Army Medical College Rawalpindi 2020
Materias:
R
Acceso en línea:https://doaj.org/article/5c721ef91d3e495f8c8a5120fcf88bf7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5c721ef91d3e495f8c8a5120fcf88bf7
record_format dspace
spelling oai:doaj.org-article:5c721ef91d3e495f8c8a5120fcf88bf72021-12-02T14:54:22ZROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILUREdoi.org/10.51253/pafmj.v70i6.48690030-96482411-8842https://doaj.org/article/5c721ef91d3e495f8c8a5120fcf88bf72020-12-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/4869https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To compare mean heart rate reduction in Ivabradine and placebo group in left ventricular failure patients. Study Design: Quasi experimental study. Place and Duration of Study: Study was conducted at CMH, Kharian, from Jul 2018 to Dec 2018. Methodology: 64 patients participated in the study. They were randomly divided into two groups of 32 each. One group was given Tab Ivabradine (10 mg twice a day) while second group received a placebo for a period of 4 weeks. After 4 weeks each patient was evaluated and heart rate, systolic and diastolic blood pressure were recorded. Mann-whitney U test selected to compare heart rate and ages of both groups t- test used to compare systolic and diastolic blood pressure among both groups. Chi-square test used to determine the association of heart rate between two groups. A p-value ≤0.05 was considered significant. Results: Median (IQR) heart rate was significantly lower in Ivabradine group 58.3 (4) as compared to placebo 64.1(1) (p<0.01). Systolic blood pressure (132.8 ± 3.6) was significantly lower in ivabradine group as compared to placebo group (137.1 ± 4.5) (p<0.01). Difference in diastolic blood pressure was insignificant in both groups (p=0.55). There was a significant association between heart rate of 55-60 beats per minute and ivabradine use (p<0.01). Conclusion: Ivabradine is safe and efficative drug in reducing heart rate and systolic blood pressure for patients suffering from left ventricular failure. Early detection and management of left ventricular failure with ivabradine use leads to better prognosis of the disease.Safia BatoolJamal WarisMuhammad Usman SajidShazia NisarImran KhanHina MushtaqArmy Medical College Rawalpindiarticleheart rateivabradineleft ventricular failureMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 70, Iss 6, Pp 1839-1842 (2020)
institution DOAJ
collection DOAJ
language EN
topic heart rate
ivabradine
left ventricular failure
Medicine
R
Medicine (General)
R5-920
spellingShingle heart rate
ivabradine
left ventricular failure
Medicine
R
Medicine (General)
R5-920
Safia Batool
Jamal Waris
Muhammad Usman Sajid
Shazia Nisar
Imran Khan
Hina Mushtaq
ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE
description Objective: To compare mean heart rate reduction in Ivabradine and placebo group in left ventricular failure patients. Study Design: Quasi experimental study. Place and Duration of Study: Study was conducted at CMH, Kharian, from Jul 2018 to Dec 2018. Methodology: 64 patients participated in the study. They were randomly divided into two groups of 32 each. One group was given Tab Ivabradine (10 mg twice a day) while second group received a placebo for a period of 4 weeks. After 4 weeks each patient was evaluated and heart rate, systolic and diastolic blood pressure were recorded. Mann-whitney U test selected to compare heart rate and ages of both groups t- test used to compare systolic and diastolic blood pressure among both groups. Chi-square test used to determine the association of heart rate between two groups. A p-value ≤0.05 was considered significant. Results: Median (IQR) heart rate was significantly lower in Ivabradine group 58.3 (4) as compared to placebo 64.1(1) (p<0.01). Systolic blood pressure (132.8 ± 3.6) was significantly lower in ivabradine group as compared to placebo group (137.1 ± 4.5) (p<0.01). Difference in diastolic blood pressure was insignificant in both groups (p=0.55). There was a significant association between heart rate of 55-60 beats per minute and ivabradine use (p<0.01). Conclusion: Ivabradine is safe and efficative drug in reducing heart rate and systolic blood pressure for patients suffering from left ventricular failure. Early detection and management of left ventricular failure with ivabradine use leads to better prognosis of the disease.
format article
author Safia Batool
Jamal Waris
Muhammad Usman Sajid
Shazia Nisar
Imran Khan
Hina Mushtaq
author_facet Safia Batool
Jamal Waris
Muhammad Usman Sajid
Shazia Nisar
Imran Khan
Hina Mushtaq
author_sort Safia Batool
title ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE
title_short ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE
title_full ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE
title_fullStr ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE
title_full_unstemmed ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE
title_sort role of heart rate reduction with ivabradine in left ventricular failure
publisher Army Medical College Rawalpindi
publishDate 2020
url https://doaj.org/article/5c721ef91d3e495f8c8a5120fcf88bf7
work_keys_str_mv AT safiabatool roleofheartratereductionwithivabradineinleftventricularfailure
AT jamalwaris roleofheartratereductionwithivabradineinleftventricularfailure
AT muhammadusmansajid roleofheartratereductionwithivabradineinleftventricularfailure
AT shazianisar roleofheartratereductionwithivabradineinleftventricularfailure
AT imrankhan roleofheartratereductionwithivabradineinleftventricularfailure
AT hinamushtaq roleofheartratereductionwithivabradineinleftventricularfailure
_version_ 1718389386721099776